Evaluating the Long-Term Cost-Effectiveness of the English NHS Diabetes Prevention Programme using a Markov Model

被引:0
|
作者
McManus, Emma [1 ]
机构
[1] Univ Manchester, Fac Biol Med & Hlth, Sch Hlth Sci, Hlth Org Policy & Econ,Div Populat Hlth Hlth Serv, Suite 12,Floor 7,Williamson Bldg,Oxford Rd, Manchester M13 9PL, England
关键词
LIFE-STYLE INTERVENTION; UNITED-KINGDOM; RISK; CARE; METFORMIN; ADULTS; IDENTIFICATION; STRATEGIES; MELLITUS; PEOPLE;
D O I
10.1007/s41669-024-00487-6
中图分类号
F [经济];
学科分类号
02 ;
摘要
Background In 2016, England launched the largest nationwide diabetes mellitus prevention programme, the NHS Diabetes Prevention Programme (NHS DPP). This paper seeks to evaluate the long-term cost-effectiveness of this programme.Methods A Markov cohort state transition model was developed with a 35-year time horizon and yearly cycles to compare referral to the NHS DPP to usual care for individuals with non-diabetic hyperglycaemia. The modelled cohort of individuals mirrored the age profile of referrals received by the programme by April 2020. A health system perspective was taken, with costs in UK pound Sterling (price year 2020) and outcomes in terms of quality-adjusted life-years (QALYs). Probabilistic analysis with 10,000 Monte Carlo simulations was used. Several sensitivity analyses were conducted to explore the uncertainty surrounding the base case results, particularly varying the length of time for which the effectiveness of the programme was expected to last.Results In the base case, using only the observed effectiveness of the NHS DPP at 3 years, it was found that the programme is likely to dominate usual care, by generating on average 40.8 incremental QALYs whilst saving 135,755 pound in costs for a cohort of 1000. At a willingness to pay of 20,000 pound per QALY, 98.1% of simulations were on or under the willingness-to-pay threshold. Scaling this up to the number of referrals actually received by the NHS DPP prior to April 2020, cost savings of 71.4 pound million were estimated over the 35-year time horizon and an additional 21,472 QALYs generated. These results are robust to several sensitivity analyses.Conclusion The NHS DPP is likely to be cost-effective. Indeed, in the majority of the simulations, the NHS DPP was cost-saving and generated greater QALYs, dominating usual care. This research should serve as evidence to support the continued investment or recommissioning of diabetes prevention programmes.
引用
收藏
页码:569 / 583
页数:15
相关论文
共 50 条
  • [21] Evaluating the Long-Term Cost-Effectiveness of Daily Administered GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes in the United Kingdom
    Hunt, Barnaby
    Ye, Qing
    Valentine, William J.
    Ashley, Donna
    DIABETES THERAPY, 2017, 8 (01) : 129 - 147
  • [22] Long-Term Cost-Effectiveness of Disease Management in Systolic Heart Failure
    Miller, George
    Randolph, Stephen
    Forkner, Emma
    Smith, Brad
    Galbreath, Autumn Dawn
    MEDICAL DECISION MAKING, 2009, 29 (03) : 325 - 333
  • [23] Long-term cost-effectiveness of interventions for obesity: A mendelian randomisation study
    Harrison, Sean
    Dixon, Padraig
    Jones, Hayley E.
    Davies, Alisha R.
    Howe, Laura D.
    Davies, Neil M.
    PLOS MEDICINE, 2021, 18 (08)
  • [24] Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction
    Magnuson, Elizabeth A.
    Li, Haiyan
    Wang, Kaijun
    Vilain, Katherine
    Shafiq, Ali
    Bonaca, Marc P.
    Bhatt, Deepak L.
    Cohen, Marc
    Steg, Philippe Gabriel
    Storey, Robert F.
    Braunwald, Eugene
    Sabatine, Marc S.
    Cohen, David J.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 70 (05) : 527 - 538
  • [25] Long-term cost-effectiveness of collaborative care (vs usual care) for people with depression and comorbid diabetes or cardiovascular disease: a Markov model informed by the COINCIDE randomised controlled trial
    Camacho, Elizabeth M.
    Ntais, Dionysios
    Coventry, Peter
    Bower, Peter
    Lovell, Karina
    Chew-Graham, Carolyn
    Baguley, Clare
    Gask, Linda
    Dickens, Chris
    Davies, Linda M.
    BMJ OPEN, 2016, 6 (10):
  • [26] Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK
    Ramos, Mafalda
    Cummings, Michael H.
    Ustyugova, Anastasia
    Raza, Syed, I
    de Silva, Shamika U.
    Lamotte, Mark
    DIABETES THERAPY, 2020, 11 (09) : 2041 - 2055
  • [27] Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus other treatment regimens in the chinese type 2 diabetes patients
    Wei, Ran
    Wang, Weihao
    Huang, Xiusheng
    Qiao, Jingtao
    Huang, Jinghe
    Xing, Chang
    Pan, Qi
    Guo, Lixin
    DIABETOLOGY & METABOLIC SYNDROME, 2023, 15 (01)
  • [28] Long-term cost-effectiveness of implementing a lifestyle intervention during pregnancy to reduce the incidence of gestational diabetes and type 2 diabetes
    Lloyd, Melanie
    Morton, Jedidiah
    Teede, Helena
    Marquina, Clara
    Abushanab, Dina
    Magliano, Dianna J.
    Callander, Emily J.
    Ademi, Zanfina
    DIABETOLOGIA, 2023, 66 (07) : 1223 - 1234
  • [29] Cost-Effectiveness and Long-Term Savings of the Bright Bodies Intervention for Childhood Obesity
    Pryor, Sydney
    Savoye, Mary
    Nowicka, Paulina
    Price, Gary
    Sharifi, Mona
    Yaesoubi, Reza
    VALUE IN HEALTH, 2023, 26 (08) : 1183 - 1191
  • [30] Modeling the Long-Term Cost-Effectiveness of the Caries Management System in an Australian Population
    Warren, Emma
    Pollicino, Christine
    Curtis, Bradley
    Evans, Wendell
    Sbaraini, Alexandra
    Schwarz, Eli
    VALUE IN HEALTH, 2010, 13 (06) : 750 - 760